2341-22-2, Flurocitabine,
CAS:2341-22-2
C9H12FN3O5 / 261.21
MFCD00210953
5-Fluorocytidine (5FC) is an analogue of cytidine, a nucleoside that exists in both RNA and DNA. 5FC was first described in 1957 as a potential treatment for cancer due to its ability to incorporate into DNA, ultimately leading to cell death. Since then, 5FC has been used as an antifungal agent, antiviral agent, and as a tool for studying cellular metabolism.
Synthesis and Characterization:
5FC is synthesized from cytidine by fluorination of the 5-position using fluorine gas. Several methods have been developed for the synthesis of 5FC, including the use of trifluoromethanesulfonic acid, silver fluoride, and antimony trifluoride. The purity and identity of synthesized 5FC is typically characterized using analytical methods such as chromatography and spectroscopy.
Analytical Methods:
Several analytical methods have been developed for the detection and quantification of 5FC. These include high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance spectroscopy (NMR).
Biological Properties:
5FC is converted by the enzyme cytosine deaminase (CD) into 5-fluorouracil (5FU), which is a potent chemotherapy agent. 5FC has also been shown to have antifungal properties by inhibiting fungal protein synthesis. Additionally, 5FC has antiviral activity against several RNA viruses, including hepatitis C virus and HIV-1.
Toxicity and Safety in Scientific Experiments:
While 5FC is generally considered safe, toxicity studies have been conducted to evaluate its potential side effects. Studies have shown that high doses of 5FC can cause liver toxicity, bone marrow suppression, and gastrointestinal side effects. However, these side effects were only observed at doses much higher than those used in clinical practice.
Applications in Scientific Experiments:
5FC has been used as a tool for studying cellular metabolism, as it is incorporated into both DNA and RNA. Additionally, 5FC is commonly used as a selective agent in molecular biology experiments to select for cells that have been transfected with the CD gene.
Current State of Research:
Current research on 5FC focuses on developing new methods for synthesizing 5FC and improving its antifungal and antiviral properties. Additionally, research is being conducted on the use of 5FC as a vector for gene therapy, as it can be used to selectively kill cancer cells that have been transfected with the CD gene.
Potential Implications in Various Fields of Research and Industry:
The potential implications of 5FC in scientific research and industry are vast. 5FC has the potential to be used as a chemotherapeutic agent for several types of cancer, including colon, liver, and breast cancer. Additionally, 5FC has been used to treat fungal infections, such as candidiasis and cryptococcosis. The antiviral properties of 5FC also make it a promising candidate for the treatment of viral infections.
Limitations and Future Directions:
Despite its potential, there are limitations to the use of 5FC. Resistance to 5FC can develop in cancer cells and fungi, leading to treatment failure. The potential applications of 5FC in gene therapy are also limited by the need to transfect cells with the CD gene. Future directions for research on 5FC include developing new methods for improving its efficacy as a chemotherapeutic agent and studying its potential use in combination with other drugs. Additionally, further research is needed on the use of 5FC in gene therapy and its potential applications in treating viral infections.
5-Fluorocytidine (5FC) is an antiviral drug that inhibits the synthesis of DNA. 5FC is a prodrug that is converted to cytosine in vivo, and then incorporated into viral DNA by polymerase chain reactions. The incorporation of 5FC into viral DNA prevents replication and transcription, which can lead to the death of cells infected with HIV. In addition, 5FC has been shown to be effective in treating chronic viral hepatitis and bowel diseases such as Crohn's disease. It also has potential use as a drug target for cancer treatments. 5FC has been shown to inhibit transcription activators in murine hepatoma cells and inhibit the growth of tumors in transfection experiments using human colon cancer cells.
CAS Number | 2341-22-2 |
Product Name | 5-Fluorocytidine |
IUPAC Name | 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidin-2-one |
Molecular Formula | C9H12FN3O5 |
Molecular Weight | 261.21 g/mol |
InChI | InChI=1S/C9H12FN3O5/c10-3-1-13(9(17)12-7(3)11)8-6(16)5(15)4(2-14)18-8/h1,4-6,8,14-16H,2H2,(H2,11,12,17)/t4-,5-,6-,8-/m1/s1 |
InChI Key | STRZQWQNZQMHQR-UAKXSSHOSA-N |
SMILES | C1=C(C(=NC(=O)N1C2C(C(C(O2)CO)O)O)N)F |
Synonyms | 5-fluoro-cytidine, 5-fluorocytidine, 5-fluorocytidine monohydrochloride |
Canonical SMILES | C1=C(C(=NC(=O)N1C2C(C(C(O2)CO)O)O)N)F |
Isomeric SMILES | C1=C(C(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)F |
CAS No: 2341-22-2 Synonyms: 5-Fluoro-D-cytidine MDL No: MFCD00210953 Chemical Formula: C9H12FN3O5 Molecular Weight: 261.21 | |
References: 1. Yasuyuki N, Masanori M, Hiroyuki E, Hiroshi S, Kaori F, Masako I, Isao U, Katuteru Y, Hideo I, Cancer Science 1990, 81, p188 |
Contact: Miss.Xing
Phone: 18310328607 , 13621067991,13552979007
Tel: 86+10-61274189
Email: chemsynlab@163.com, zhangchao@chemsynlab.com
Add: A411 Room,No.26,Jinyuan Road,Daxing Industrial Developing District,Beijing,China post code:102628